About FARA
Mission & Organization
Financials
Leadership & Staff
Scientific Advisory Board
FARA Ambassador Program
Our Partners
Advocacy
Media
News & Press Releases
Video Resources
Upcoming Activities & Events
Contact
Research
Grant Program
Clinical Network & Trials
Scientific Conferences
Patient Registry
FARA Directed Projects
FARA Funded Research
Research Pipeline
For Pharmaceutical Professionals
Research Resources
For Physicians
Institutional Supported Programs
The FA CollaMap
Clinical Care Guidelines
Autopsy & Tissue Donation
Featured Scientists
Scientific News
Regulatory Interactions
Living with FA
What is FA?
Message for New Families
Participation in Clinical Trials
Clinical Care
Clinical Care Guidelines
Patient Registry
Meet the Community
Family Support & Resources
Ataxian Athlete Initiative
Ways to Help
Ways to Donate
rideATAXIA
Team FARA
FARA Energy Ball
Grassroots Fundraising
Shop the FARA Store
Fundraising Tools
Legacy Giving
Raising Awareness
Advocacy
Memorials
Upcoming Activities & Events
What is FA?
Search
FDA Grants Orphan Drug Designation to EPI-743 and Allows Expanded Access in Mitochondrial Diseases Including Friedreich’s Ataxia
Details
Written: Wednesday, June 8, 2011
pdf/news/2011/FDAOrphanDrugDesignationEPI-743.pdf
